# Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception

> **NCT02446821** · PHASE2 · COMPLETED · sponsor: **Sebela Women's Health Inc.** · enrollment: 286 (actual)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** VeraCept

## Key facts

- **NCT ID:** NCT02446821
- **Lead sponsor:** Sebela Women's Health Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-05
- **Final completion:** 2019-03-22
- **Target enrollment:** 286 (ACTUAL)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446821, "Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02446821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*